395 related articles for article (PubMed ID: 32117981)
1. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.
Wang H; Rao B; Lou J; Li J; Liu Z; Li A; Cui G; Ren Z; Yu Z
Front Cell Dev Biol; 2020; 8():55. PubMed ID: 32117981
[TBL] [Abstract][Full Text] [Related]
2. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
3. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.
Venepalli NK; Goff L
Int J Hepatol; 2013; 2013():341636. PubMed ID: 23606971
[TBL] [Abstract][Full Text] [Related]
4. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
5. Targeting hepatocyte growth factor/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies.
Yu J; Chen GG; Lai PBS
Med Res Rev; 2021 Jan; 41(1):507-524. PubMed ID: 33026703
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
7. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
Xiang QF; Zhan MX; Li Y; Liang H; Hu C; Huang YM; Xiao J; He X; Xin YJ; Chen MS; Lu LG
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):83-89. PubMed ID: 30663411
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy.
Liu X; Sun R; Chen J; Liu L; Cui X; Shen S; Cui G; Ren Z; Yu Z
Front Cell Dev Biol; 2020; 8():23. PubMed ID: 32083078
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
[TBL] [Abstract][Full Text] [Related]
12. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
13. SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma.
Zhang W; Sun H; Shi X; Wang H; Cui C; Xiao F; Wu C; Guo X; Wang L
Tumour Biol; 2016 Jun; 37(6):7741-8. PubMed ID: 26695141
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
15. The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells.
İşcan E; Güneş A; Korhan P; Yılmaz Y; Erdal E; Atabey N
J Cell Commun Signal; 2017 Jun; 11(2):155-166. PubMed ID: 27975162
[TBL] [Abstract][Full Text] [Related]
16. Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.
Zhuang PH; Xu L; Gao L; Lu W; Ruan LT; Yang J
Onco Targets Ther; 2017; 10():847-857. PubMed ID: 28243120
[TBL] [Abstract][Full Text] [Related]
17. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
18. The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.
Hu CT; Wu JR; Cheng CC; Wu WS
Cancers (Basel); 2017 May; 9(6):. PubMed ID: 28587113
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
[TBL] [Abstract][Full Text] [Related]
20. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma.
Lee JJX; Chan JJ; Choo SP
Diseases; 2015 Oct; 3(4):306-324. PubMed ID: 28943627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
